Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
ANAB

AnaptysBio

$64.67

-2.07 (-3.10%)

16:13
10/20/17
10/20
16:13
10/20/17
16:13
Hot Stocks
Breaking Hot Stocks news story on AnaptysBio »

Cormorant Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

Over a week ago
ANAB

AnaptysBio

21:08
10/12/17
10/12
21:08
10/12/17
21:08
Syndicate
AnaptysBio 3M share Secondary priced at $68.50 »

Credit Suisse, Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 13

    Oct

ANAB

AnaptysBio

$70.41

35.41 (101.17%)

, SNY

Sanofi

$50.10

-0.32 (-0.63%)

08:08
10/11/17
10/11
08:08
10/11/17
08:08
Recommendations
AnaptysBio, Sanofi, Regeneron analyst commentary at Baird »

AnaptysBio price target…

ANAB

AnaptysBio

$70.41

35.41 (101.17%)

SNY

Sanofi

$50.10

-0.32 (-0.63%)

REGN

Regeneron

$461.13

-8.43 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 06

    Nov

  • 13

    Oct

ANAB

AnaptysBio

$70.41

35.41 (101.17%)

16:07
10/10/17
10/10
16:07
10/10/17
16:07
Syndicate
AnaptysBio files to sell 3M shares of common stock »

Credit Suisse, Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 06

    Nov

ANAB

AnaptysBio

14:49
10/10/17
10/10
14:49
10/10/17
14:49
Recommendations
AnaptysBio analyst commentary at JMP Securities »

AnaptysBio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 06

    Nov

ANAB

AnaptysBio

$35.00

-0.68 (-1.91%)

14:25
10/10/17
10/10
14:25
10/10/17
14:25
Recommendations
AnaptysBio analyst commentary at RBC Capital »

AnaptysBio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 06

    Nov

ANAB

AnaptysBio

12:34
10/10/17
10/10
12:34
10/10/17
12:34
Recommendations
AnaptysBio analyst commentary at Credit Suisse »

AnaptysBio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 06

    Nov

ANAB

AnaptysBio

$35.00

-0.68 (-1.91%)

08:25
10/10/17
10/10
08:25
10/10/17
08:25
Conference/Events
AnaptysBio to hold a pharmaceutical update conference call »

Management announces and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 06

    Nov

ANAB

AnaptysBio

$35.00

-0.68 (-1.91%)

07:09
10/10/17
10/10
07:09
10/10/17
07:09
Conference/Events
AnaptysBio to hold a pharmaceutical update conference call »

Management announces and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 06

    Nov

ANAB

AnaptysBio

$35.00

-0.68 (-1.91%)

06:32
10/10/17
10/10
06:32
10/10/17
06:32
Hot Stocks
AnaptysBio reports 'positive' results from Phase 2a clinical trial of ANB020 »

AnaptysBio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.